Progresión y manejo de la neoplasia duodenal en la poliposis adenomatosa familiar

1. Vasen HF, Moslein G, Alonso A, et al. Guidelines for the clinical management of familial adenomatous adenomatosis (FAP). Gut. 2008;57:704–713.
2. Nugent KP, Spigelman AD, Phillips RK. Life expectancy after colectomy and ileorectal anastomosis for familial adenomatous adenomatosis. Dis Colon Rectum. 1993;36:1059–1062.
3. Spigelman AD, Williams CB, Talbot IC, et al. Upper gastrointestinal cancer in patients with familial adenomatous adenomatosis. Lancet. 1989;2:783–785.
4. Jagelman DG, DeCosse JJ, Bussey HJ. Upper gastrointestinal cancer in familial adenomatous adenomatosis. Lancet. 1988;1:1149–1151.
5. Moozar KL, Madlensky L, Berk T, et al. Slow progression of periampullary neoplasia in familial adenomatous adenomatosis. J Gastrointest Surg. 2002;6:831–837; discussion 837.
6. Vasen HF, Bulow S, Myrhoj T, et al. Decision analysis in the management of duodenal adenomatosis in familial adenomatous adenomatosis. Gut. 1997;40:716–719.
7. Sanabria JR, Croxford R, Berk TC, et al. Familial segregation in the occurrence and severity of periampullary neoplasms in familial adenomatous adenomatosis. Am J Surg. 1996;171:136–140; discussion 140–141.
8. Spigelman AD, Talbot IC, Penna C, et al. Evidence for adenoma-carcinoma sequence in the duodenum of patients with familial adenomatous adenomatosis. The Leeds Castle Adenomatosis Group (Upper Gastrointestinal Committee). J Clin Pathol. 1994;47:709–710.
9. Sawada T, Muto T. Role of upper gastrointestinal surveillance in patients with familial adenomatous adenomatosis. Gastrointest Endosc Clin N Am. 1997;7:99–111.
10. Groves CJ, Saunders BP, Spigelman AD, et al. Duodenal cancer in patients with familial adenomatous adenomatosis (FAP): results of a 10 year prospective study. Gut. 2002;50:636–641.
11. Bulow S, Christensen IJ, Hojen H, et al. Duodenal surveillance improves the prognosis after duodenal cancer in familial adenomatous adenomatosis. Colorectal Dis. 2012;14:947–952.
12. Lepisto A, Kiviluoto T, Halttunen J, et al. Surveillance and treatment of duodenal adenomatosis in familial adenomatous adenomatosis. Endoscopy. 2009;41:504–509.
13. Penna C, Phillips RK, Tiret E, et al. Surgical polypectomy of duodenal adenomas in familial adenomatous adenomatosis: experience of two European centres. Br J Surg. 1993;80:1027–1029.
14. Offerhaus GJ, Giardiello FM, Krush AJ, et al. The risk of upper gastrointestinal cancer in familial adenomatous adenomatosis. Gastroenterology. 1992;102:1980–1982.
15. Brosens LA, Keller JJ, Offerhaus GJ, et al. Prevention and management of duodenal polyps in familial adenomatous adenomatosis. Gut. 2005;54:1034–1043.
16. Balmforth DC, Phillips RK, Clark SK. Advanced duodenal disease in familial adenomatous adenomatosis: how frequently should patients be followed up after successful therapy? Fam Cancer. 2012;11:553–557.
17. Jasperson KW, Burt RW. APC-associated polyposis conditions. In: Pagon RA, Adam MP, Ardinger HH, et al, eds. GeneReviews® [Internet]. Seattle, WA: University of Washington. Available at: http://www.ncbi.nlm.nih.gov/books/NBK1345/. Published December 18, 1998. Updated March 27, 2014. Accessed May 16, 2014.
18. Soravia C, Berk T, Haber G, et al. Management of advanced duodenal adenomatosis in familial adenomatous adenomatosis. J Gastrointest Surg. 1997;1:474–478.
19. Riddell RH, Goldman H, Ransohoff DF, et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol. 1983;14:931–968.
20. Lauwers GY, Riddell RH. Gastric epithelial dysplasia. Gut. 1999;45:784–790.
21. Genta RM, Feagins LA. Advanced precancerous lesions in the small bowel mucosa. Best Pract Res Clin Gastroenterol. 2013;27:225–233.
22. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–213.
23. Bassi C, Dervenis C, Butturini G, et al. Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery. 2005;138:8–13.
24. Bulow S, Bjork J, Christensen IJ, et al. Duodenal adenomatosis in familial adenomatous adenomatosis. Gut. 2004;53:381–386.
25. Spigelman AD, Williams CB, Phillips RK. Rectal adenomatosis as a guide to duodenal adenomatosis in familial adenomatous adenomatosis. J R Soc Med. 1992;85:77–79.
26. Debinski HS, Spigelman AD, Hatfield A, et al. Upper intestinal surveillance in familial adenomatous adenomatosis. Eur J Cancer. 1995;31A:1149–1153.
27. Kadmon M, Tandara A, Herfarth C. Duodenal adenomatosis in familial adenomatous adenomatosis coli: a review of the literature and results from the Heidelberg Adenomatosis Register. Int J Colorectal Dis. 2001;16:63–75.
28. Jaganmohan S, Lynch PM, Raju RP, et al. Endoscopic management of duodenal adenomas in familial adenomatous adenomatosis: a single-center experience. Dig Dis Sci. 2012;57:732–737.
29. de Vos tot Nederveen Cappel WH, Jarvinen HJ, Bjork J, et al. Worldwide survey among adenomatosis registries of surgical management of severe duodenal adenomatosis in familial adenomatous adenomatosis. Br J Surg. 2003;90:705–710.
30. Richard CS, Berk T, Bapat BV, et al. Sulindac for periampullary polyps in FAP patients. Int J Colorectal Dis. 1997;12:14–18.
31. Phillips RK, Wallace MH, Lynch PM, et al. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal adenomatosis in familial adenomatous adenomatosis. Gut. 2002;50:857–860.
32. Gallagher MC, Shankar A, Groves CJ, et al. Pylorus-preserving pancreaticoduodenectomy for advanced duodenal disease in familial adenomatous adenomatosis. Br J Surg. 2004;91:1157–1164